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SETTING: Thyolo, rural southern Malawi.
OBJECTIVES: To determine 1) the proportion who con-
tinue with cotrimoxazole prophylaxis for the prevention
of opportunistic infections, and 2) the reasons for con-
tinuing or stopping prophylaxis, in human immuno-
deﬁciency virus (HIV) infected individuals with tuber-
culosis (TB) who complete anti-tuberculosis treatment.
DESIGN: A cross-sectional study.
METHODS: A questionnaire study of all HIV-infected
TB patients who had been registered over a 3-month
period to receive anti-tuberculosis treatment and cotri-
moxazole prophylaxis and who had completed anti-
tuberculosis treatment 3–6 months earlier.
RESULTS: Of 82 HIV-infected individuals who were
alive at the time of interview, 76 (93%) were continuing
with cotrimoxazole and wished to do so indeﬁnitely. The
most common reason for continuing the drug was to
prevent illness associated with HIV, while the most com-
mon reason for stopping was long distances to the health
facility. Ninety-six percent of patients received cotri-
moxazole free of charge from a health centre. Of those
who wished to continue indeﬁnitely, the majority (63%)
could not afford to pay for the drug.
CONCLUSIONS: In a rural setting, the great majority of
HIV-infected individuals continued with cotrimoxazole
after completing anti-tuberculosis treatment. Making the
drug available and providing it free of charge is essential if
it is to remain accessible for longer term prevention.
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PATIENTS INFECTED with the human immuno-
deﬁciency virus (HIV) and tuberculosis (TB) in sub-
Saharan Africa have high death rates during and after
anti-tuberculosis treatment.1,2 Opportunistic infec-
tions are an important cause of the high morbidity
and mortality experienced by these patients,3–5 and it
is believed that interventions to prevent these infec-
tions might improve survival. Prophylaxis with cotri-
moxazole has been shown to reduce morbidity and
mortality in HIV-infected patients with smear-positive
pulmonary tuberculosis (PTB) in Côte d’Ivoire,6 and
in 2000, UNAIDS made provisional recommenda-
tions that cotrimoxazole prophylaxis be given to all
persons living with HIV/AIDS in Africa.7
Since early 1999, Thyolo District, in rural south-
ern Malawi, has been offering voluntary counselling
and HIV testing (VCT) to all TB patients, followed by
adjunctive cotrimoxazole treatment to those found to
be infected with HIV. The district is currently assess-
ing the feasibility and effectiveness of this interven-
tion in reducing death rates.8 During anti-tuberculosis
treatment, HIV-infected TB patients receive anti-
tuberculosis drugs as well as cotrimoxazole under the
supervision of the TB control programme. This respon-
sibility ceases at the end of anti-tuberculosis treat-
ment, and patients are simply encouraged to continue
with cotrimoxazole, the decision being left princi-
pally with the patient. Information as to whether
patients are continuing with cotrimoxazole prophylaxis
after anti-tuberculosis treatment, and possible factors
that encourage or discourage continuation of prophy-
laxis would be useful to the general health services in
planning for cotrimoxazole prophylaxis after anti-
tuberculosis treatment. It might also give insight into
the value of cotrimoxazole as perceived by the patient.
This study was conducted in a cohort of HIV-
infected individuals 3 to 6 months after they had
completed anti-tuberculosis treatment, in order to
determine 1) the proportion of patients still taking
cotrimoxazole prophylaxis, and 2) their reasons for




The study was carried out between February and
March 2002 in Thyolo District, in rural southern
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Malawi, which has a population of 450000. The dis-
trict has one government hospital, a mission hospital
and 18 health centres involved in TB control activi-
ties. In this district, all patients (adults and children)
diagnosed with TB are registered and started on stan-
dardised anti-tuberculosis treatment according to
national guidelines.9 Patients undergo VCT, and are
offered cotrimoxazole prophylaxis if they are HIV-
seropositive and there are no contraindications to the
medication. Cotrimoxazole prophylaxis is offered at
a dose of 480 mg (400 mg sulfamethoxazole and 80
mg trimethoprim) twice daily in adults and according
to weight (kg) in two divided doses in children. The
drug is taken throughout the whole course of anti-
tuberculosis treatment and indeﬁnitely thereafter. Early
in the course of initiating cotrimoxazole in our set-
ting, it was observed that several patients complained
of severe nausea and vomiting when the drug was
given once daily in the morning along with the anti-
tuberculosis drugs. Twice-daily dosing was therefore
introduced, and continued as patients experienced
fewer reactions.
Anti-tuberculosis drugs and both daily doses of
cotrimoxazole are administered by direct observation
by the health worker during the initial phase of treat-
ment. In the continuation phase, the anti-tuberculosis
drugs and cotrimoxazole are given to patients at
monthly intervals at their nearest health facility, and
the drugs are self-administered.
At the end of anti-tuberculosis treatment, HIV-
infected individuals can collect their cotrimoxazole
for prophylaxis on a monthly basis from health cen-
tres, where a special stock is made available for this
purpose, through nurses in areas where home-based
care services exist, or from public pharmacies and ven-
dors at a cost. The drugs provided by the health cen-
tres and home-based care services are free of charge.
Study population and data collection
All TB patients with known HIV infection who had
been registered over a 3-month period to receive anti-
tuberculosis treatment as well as cotrimoxazole prophy-
laxis and who had completed anti-tuberculosis treat-
ment 3 to 6 months earlier were involved in the study.
TB treatment and counselling registers were used
to gather information on patients who were alive at
the end of their anti-tuberculosis treatment. A house-
hold visit was conducted for each patient known to
be alive. After obtaining informed consent, inter-
viewer-administered questionnaires which had been
pre-tested on a different group of 10 HIV-infected TB
patients were used to gather basic socio-demographic
data and information related to cotrimoxazole pro-
phylaxis. In the design of the questionnaire, patients
were asked to give their main reasons for continuing
or stopping cotrimoxazole after completing anti-
tuberculosis treatment. In the case of children, the
father or mother was interviewed. Cotrimoxazole
availability at the patient’s home was physically veri-
ﬁed by requesting to see the tablet package. The inter-
views were conducted in the local language by expe-
rienced interviewers, and the same team was used
throughout the study.
Analyses were performed using Epi-Info soft-
ware (Centre for Disease Control and Prevention,
Atlanta, GA).
RESULTS
Study population, VCT and adjunctive
cotrimoxazole prophylaxis
A total of 219 TB patients were registered in the 3-
month study cohort. Of these, 212 (97%) received
pre-test counselling, 204 (93%) underwent HIV test-
ing and 199 (91%) received post-test counselling. The
HIV status was unknown for 15 patients: ﬁve refused
HIV testing, six died, two were transferred out of the dis-
trict and two had missed pre-test counselling (Figure).
Of the 204 TB patients who were HIV-tested (66
on standard treatment and 138 on short-course treat-
ment), 149 (69%) were HIV-positive: this included
75 (65%) of 114 patients with smear-positive PTB,
41 (85%) of 48 with smear-negative PTB and 33
Figure Proﬁle of the study cohort followed up after complet-
ing anti-tuberculosis treatment. *35 smear-negative PTB and
32 EPTB cases on 1SEH/11EH; †125 smear-positives and 13 se-
vere smear-negatives/EPTB on 2SRHZ/6EH, six children on
2R3H3E3/6EH, and 8 relapses on 2 SRHZE/1RHZE/ 5R3H3Z3E3. PTB  
pulmonary tuberculosis; EPTB   extra-pulmonary tuberculosis;
S   streptomycin; E   ethambutol; H   isoniazid; R   rifampi-
cin; Z   pyrazinamide. (A regimen consists of two phases—an
initial phase and continuation phase. Numbers before the let-
ters indicate the duration of that phase in months; numbers in
subscript indicate the number of doses of the drug(s) per week.
If there is no subscript, the treatment with that drug is daily.)1048 The International Journal of Tuberculosis and Lung Disease
(78%) of 42 patients with extra-pulmonary TB
(EPTB). Of the 149 HIV-infected TB patients, 146
(98%) were given cotrimoxazole after VCT within a
mean period of 2 days after registration (Figure).
Of those placed on anti-tuberculosis treatment and
cotrimoxazole, 44 (20% of the registered cohort) died
during the course of their anti-tuberculosis treatment,
and 19 (9%) died after completing their treatment.
One patient was transferred out during treatment and
was lost to follow-up.
Of the 82 individuals on cotrimoxazole who were
ﬁnally interviewed, there were 34 men, 47 (57%)
women and one child. The median age was 32 years
(range 5 to 58), and the median educational level was
6 years of schooling (range 0–14). Forty-nine (60%)
patients were married and 33 were single (unmarried,
divorced or widowed, or a child). The commonest
occupations were farming in 46 (56%), unskilled
work in 17 (21%), business in 10 (12%) and skilled
work in six (7%) patients. Two patients had no form
of employment and the child was aged 5 years. The
majority of the patients (89%) resided in villages,
with 62% earning less than the equivalent of US $4 in
local currency per week.
Cotrimoxazole after anti-tuberculosis treatment
Eighty-two HIV-infected individuals were alive 3
to 6 months after completing anti-tuberculosis
treatment; all of them gave consent for interview.
Of these, 76 (93%) were continuing with cotri-
moxazole prophylaxis and wished to do so indeﬁ-
nitely; 54 (71%) said they would continue the drug as
they were HIV-positive and it would prevent them
from getting ill, 10 (13%) felt their life depended on
it, 10 (13%) wished to continue because it was free of
charge and two (3%) because the doctor advised it.
Of the 76 patients taking cotrimoxazole, 73
(96%) were getting their drug from a health centre
and the other three through home-based care nurses.
When asked if they could afford to start purchasing
cotrimoxazole for continuing prophylaxis, 26 (34%)
were willing to try to pay up to US $0.50 for a
month’s supply, while 50 (66%) said they would
have to stop the drug since they would not be able to
afford it.
Six individuals stopped cotrimoxazole after com-
pleting anti-tuberculosis treatment, three because
they moved to a different district that was too far
away, one because he had started working and had no
time, one felt he was ﬁne and did not need to con-
tinue, and one individual had developed a skin allergy
to the drug.
DISCUSSION
After completing anti-tuberculosis treatment, the
great majority of HIV-infected TB patients in this
study continued with cotrimoxazole prophylaxis and
wished to do so indeﬁnitely. There are a number of
encouraging ﬁndings in this respect: ﬁrst, the great
majority of HIV-infected individuals came back of
their own free will to the health centres to collect their
cotrimoxazole. During the course of anti-tuberculosis
treatment, activities linked to cotrimoxazole prophy-
laxis are integrated within the TB programme, and
patient follow-up is the responsibility of the TB ofﬁcers.
The situation is not so clear once the patient has com-
pleted anti-tuberculosis treatment when, ideally, this
responsibility should be taken over by the HIV pro-
gramme. While efforts are still underway to try to
integrate HIV and TB programme activities, making a
stock of cotrimoxazole available at the health centres
is an interim measure that will facilitate continuing
prophylaxis without adding an undue burden for
follow-up. Second, we demonstrated high compliance
with cotrimoxazole prophylaxis in HIV-infected TB
patients during the course of anti-tuberculosis treat-
ment.10 Our ﬁnding suggests that compliance remains
high even after completion of anti-tuberculosis treat-
ment. Third, the counselling process has clearly made
HIV-infected TB patients aware of the potential ben-
eﬁts of cotrimoxazole in reducing morbidity and mor-
tality. Emphasis placed on VCT in our setting and the
value as perceived by the patient is likely to enhance
compliance in the long term.
In Thyolo, cotrimoxazole is provided to patients
free of charge both during and after anti-tuberculosis
treatment. However, the question as to whether HIV-
infected individuals on a country-wide scale should
pay for cotrimoxazole or if it should be made avail-
able free of charge in Malawi has been raised. In a
rural setting such as Thyolo, the majority of patients
are either subsistence farmers or unskilled labourers
earning less than US $4 per week. Furthermore, HIV-
positive TB patients tend to be chronically ill, with a
high prevalence of moderate to severe malnutrition.11
Income generation capacity is low, and most patients
end up destitute. Although patients might therefore
desire to continue cotrimoxazole indeﬁnitely, the
majority would, quite understandably, be unable to
afford the cost.
One of the discouraging ﬁndings in this study is that
despite the fact that the great majority of HIV-positive
TB patients were on cotrimoxazole prophylaxis, cohort
mortality during anti-tuberculosis treatment remains
high. Mortality after completing anti-tuberculosis
treatment is also high, with about one in every ﬁve
HIV-infected individuals dying within 6 months of
completing anti tuberculosis treatment.
The National Tuberculosis Control Programme of
Malawi has reported rising death rates in new TB
patients, and in 1998 the country had the highest
TB death rates reported in Africa.12 Preventing early
deaths in patients with TB remains a major challenge
in resource-poor countries such as Malawi,13 and
apart from cotrimoxazole, additional effective andCotrimoxazole prophylaxis after anti-tuberculosis treatment 1049
affordable adjunctive interventions to reduce overall
death rates, including the possibility of antiretroviral
treatment, are urgently needed. Cotrimoxazole pro-
phylaxis is nevertheless the most important adjunc-
tive intervention currently available in resource-poor
settings for reducing HIV-related opportunistic infec-
tions and promoting survival during and after anti-
tuberculosis treatment. Making the drug available for
HIV-infected individuals through existing health struc-
tures and providing the drug free of charge is essential
to ensure that it remains accessible for longer term
prevention of opportunistic infections.
Acknowledgements
We are very grateful to the staff and management of Thyolo and
Malamulo hospitals for their collaboration and in particular to
members of the TB support team namely D. Chilomo, A Mbanali,
D Mbalume, T Store, R Kapangasa, and R Kwapatha.
This study received ethical approval from the National Health
Sciences Research Council of Malawi.
The study was funded by Médecins sans Frontières-Luxembourg.
References
1 De Cock K M, Soro B, Coulibaly I M, Lucas S B. Tuberculosis
and HIV infection in sub-Saharan Africa. JAMA 1992; 268:
1581–1587.
2 Raviglione M C, Harries A D, Msiska R, Wilkinson D, Nunn
P. Tuberculosis and HIV: current status in Africa. AIDS 1997;
11 (Suppl B): S115–S123.
3 Gilks C F, Brindle R J, Otieno L S, et al. Life-threatening
bacteraemia in HIV-1-seropositive adults admitted to hospital
in Nairobi, Kenya. Lancet 1990; 336: 545–549.
4 Brindle R J, Nunn P P, Batchelor B I F, et al. Infection and mor-
bidity in patients with tuberculosis in Nairobi, Kenya. AIDS
1993; 7: 1469–1474.
5 Greenberg A E, Lucas S, Tossou O, et al. Autopsy-proven
causes of death in HIV-infected patients treated for tuberculo-
sis in Abidjan, Cote d’Ivoire. AIDS 1995; 9: 1251–1254.
6 Wiktor S Z, Sassan-Morroko M, Grant A D, et al. Efﬁcacy of
trimethoprim-sulphamethoxazole prophylaxis to decrease
morbidity and mortality in HIV-1 infected patients with tuber-
culosis in Abidjan, Cote d’Ivoire: a randomised controlled
trial. Lancet 1999; 353: 1469–1475.
7 Provisional WHO/UNAIDS Secretariat recommendations on
the use of cotrimoxazole prophylaxis in adults and children liv-
ing with HIV/AIDS in Africa. Geneva, Switzerland: UNAIDS,
2000.
8 Zachariah R, Harries A D, Spielmann M P, et al. Cotrimox-
azole prophylaxis in HIV positive TB patients in a rural district
of Malawi. Abstract TuOrB278. Durban, South Africa: XIII
International AIDS Conference, 2000.
9 Manual of the National Tuberculosis Control Programme in
Malawi. 1999 4th ed. Lilongwe, Malawi: Ministry of Health
and Population.
10 Zachariah R, Harries A D, Arendt V, et al. Compliance with
cotrimoxazole prophylaxis for the prevention of opportunistic
infections in HIV-positive tuberculosis patients in Thyolo dis-
trict, Malawi. Int J Tuberc Lung Dis 2001; 5: 843–846.
11 Zachariah R, Spielmann M P, Harries A D, Salaniponi F M L.
Moderate to severe malnutrition in patients with tuberculosis
is a risk factor associated with early death. Trans Soc Trop
Med Hyg 2002; 96: 291–294.
12 World Health Organization Communicable Diseases. WHO
Report 2001. Global Tuberculosis Control. WHO/CDS/TB/
2001.287. Geneva: WHO, 2001.
13 Harries A D, Hargreaves N J, Kemp J, et al. Deaths from tuber-
culosis in sub-Saharan African countries with a high preva-
lence of HIV-1. Lancet 2001; 357: 1519–1523.
RÉSUMÉ
CADRE : Thyolo, Malawi rural du Sud.
OBJECTIFS: Déterminer, chez les patients infectés par le
virus de l’immunodéficience humaine (VIH) et atteints
de tuberculose (TB) qui ont achevé le traitement anti-
tuberculose, 1) la proportion qui poursuit une prophy-
laxie au cotrimoxazole pour la prévention des infections
opportunistes et 2) les raisons de prolongation ou d’arrêt
de la prophylaxie.
SCHÉMA : Etude transversale.
MÉTHODES: Il s’agit d’une étude par questionnaire chez
tous les patients TB infectés par le VIH qui ont été enregis-
trés pendant une période de 3 mois pour recevoir un traite-
ment anti-tuberculose et une prophylaxie au cotrimoxa-
zole et qui ont achevé le traitement anti-tuberculose de 3
à 6 mois plus tôt.
RÉSULTATS: Sur 82 individus infectés par le VIH, 76
(93%) qui étaient en vie au moment de l’entretien pour-
suivaient le traitement au cotrimoxazole et souhaitaient
le faire indéfiniment. La raison la plus fréquente pour la
poursuite de la médication a été la prévention de mala-
dies associées au VIH, alors que la raison la plus fréquente
pour son arrêt a été une distance importante du domicile au
service de santé. Le cotrimoxazole a été administré gratui-
tement à 96% des patients dans un centre de santé. Parmi
ceux qui souhaitaient poursuivre indéfiniment, la majorité
(63%) n’étaient pas à même de payer le médicament.
CONCLUSION: Dans un contexte rural, la grande
majorité des individus infectés par le VIH poursuivent le
cotrimoxazole après avoir achevé le traitement antitu-
berculeux. La mise à disposition de ce médicament et sa
gratuité sont essentielles si l’on veut qu’il reste accessible
pour une prévention de plus longue durée.
RESUMEN
MARCO DE REFERENCIA: Thyolo, región rural del sur
de Malawi.
OBJETIVO: Determinar en los sujetos con tuberculosis
(TB), infectados con el virus del inmunodeficiencia
humana (VIH), que han completado el tratamiento anti-
tuberculoso : 1) la proporción que continúa con una
profilaxis con cotrimoxazol para la prevención de las
infecciones oportunistas y 2) las razones para continuar
o suspender la profilaxis.
DISEÑO : Estudio transversal.1050 The International Journal of Tuberculosis and Lung Disease
MÉTODO: Estudio por cuestionario de todos los pacientes
con TB infectados con VIH, registrados durante un
período de 3 meses como habiendo recibido tratamiento
anti-tuberculosis y profilaxis con cotrimoxazol y que
habían completado el tratamiento anti-tuberculosis 3 a 6
meses antes.
RESULTADOS: De 82 sujetos infectados con VIH, 76
(93%) que estaban vivos en el momento de la entrevista
continuaban la profilaxis con cotrimoxazol y deseaban
hacerlo indefinidamente. La razón más frecuente para
continuar este tratamiento era la prevención de las enfer-
medades asociadas con el VIH, mientras que la razón
más frecuente para suspenderlo era la distancia impor-
tante del domicilio al centro de salud. El 96% de los
pacientes recibían el cotrimoxazol gratuitamente en el
centro de salud. Entre aquéllos que deseaban continuar
indefinidamente, la mayoría (63%) no podían hacer
frente al pago del medicamento.
CONCLUSIÓN: En un contexto rural, la gran mayoría de
los sujetos infectados con VIH continuaban con cotri-
moxazol después de haber completado el tratamiento
anti-tuberculosis. Asegurar la disponibilidad de este
medicamento y entregarlo gratuitamente es esencial si se
pretende que permanezca accesible para una prevención
de más larga duración.